Skip to Content

Aptinyx, Inc. (NYSE: APTX)

Securities Class Action

  • Date:
  • 9/20/2019
  • Company Name:
  • Aptinyx, Inc.
  • Stock Symbol:
  • APTX
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

NEW YORK, September 20, 2019 –Bragar Eagel & Squire, P.C. is investigating potential claims against Aptinyx, Inc. (NASDAQ: APTX) on behalf of Aptinyx stockholders.  Our investigation concerns whether Aptinyx has violated the federal securities laws and/or engaged in other unlawful business practices.

Aptinyx completed its IPO on June 21, 2018, offering $16.00 per share for net proceeds of $92.2 million. Aptinyx is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of synthetic molecules for the treatment of brain and nervous system disorders. NYX-2925 is an NDMA receptor modulator currently in Phase 2 clinical development.

On January 16, 2019, Aptinyx announced that its drug, NYX-2925, did not achieve statistically significant separation from the placebo on a primary end point in its phase 2 trial. On this news, shares of Aptinyx fell $11.85, or 67%, to close at $5.98. The stock has yet to recover and currently trades at around $3.28, a 79.5% decline from its IPO price

If you purchased or otherwise acquired Aptinyx shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Aptinyx. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: